

July 25, 2016

The National Stock Exchange of India Ltd  
Exchange Plaza, Bandra Kurla Complex  
Mumbai 400051

Bombay Stock Exchange Limited  
1<sup>st</sup> floor, Rotunda Building, Dalal Street  
Fort, Mumbai 400001

Dear Sir/Madam,

**Sub: Outcome of the Board meeting held today.**

With reference to the above captioned subject, we are enclosing herewith a copy of un-audited Financial Results along with the Limited Review Report for the quarter ended 30 June, 2016 as approved by the Board of Directors of the Company at its meeting held on 25 July, 2016.

The Un-audited Financial Results will be published in the newspapers within the stipulated time as per the SEBI Listing Regulations.

Kindly take the same on record.

Thanking you,

**Yours faithfully,  
For Merck Limited**



**Jeevan Mondkar**  
**Manager (Legal and Secretarial)**

Encl : As above



**Merck Limited**

Registered Office  
Godrej One, 8<sup>th</sup> Floor, Pirojshanagar  
Eastern Express Highway, Vikhroli East  
Mumbai 400079, India.  
Phone +91 22 62109000  
Fax +91 22 62109999  
www.merck.co.in  
CIN: L99999MH1967PLC013726

**MERCK LIMITED**  
 Regd. Office: Godre One, 8th Floor, Eastern Express Highway, Prapanna Nagar, Vikhroli (East), Mumbai - 400 072.  
**STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH JUNE, 2016**  
 CIN No. L99999MH1967PLC013726, email: corpsec@merckgroup.com

(Rs. in Lakhs)

Particulars	3 months ended 30/06/2016	Preceding 3 months ended 31/03/2016	Corresponding 3 months ended 30/06/2015 in the previous year	Year to date figures for the current period ended 30/06/2016	Year to date figures for the previous period ended 30/06/2015	Previous year ended 31/12/2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Income from operations</b>						
a) Net Sales/Income from operations (Net of excise duty)	26,288.13	21,290.11	24,076.63	46,548.24	43,047.43	50,832.71
b) Other operating income	516.47	529.72	650.53	1,941.19	7,355.71	3,117.33
<b>Total income from operations (net)</b>	<b>26,773.60</b>	<b>21,815.83</b>	<b>24,727.16</b>	<b>47,589.43</b>	<b>44,603.14</b>	<b>93,950.04</b>
<b>2. Expenses</b>						
a) Cost of materials consumed	9,400.10	6,051.07	6,009.94	12,251.17	12,757.57	25,092.54
b) Purchases of stock-in-trade	6,724.68	2,192.38	5,907.62	7,917.06	9,099.21	17,993.67
c) Changes in inventories of finished goods, work-in-progress and stock in trade	834.59	(67.19)	(742.26)	767.40	(1,232.27)	(161.57)
d) Employee benefits expense	3,964.81	3,528.19	3,202.58	7,493.00	6,249.95	12,338.50
e) Depreciation and amortisation expense	823.30	625.08	527.88	1,248.38	970.99	2,341.61
f) Other expenses	7,184.19	7,588.42	6,650.58	14,782.67	13,798.08	29,742.26
<b>Total expenses</b>	<b>23,741.63</b>	<b>20,717.95</b>	<b>22,616.14</b>	<b>44,459.58</b>	<b>41,641.51</b>	<b>87,947.01</b>
<b>3. Profit from operations before other income, finance costs and exceptional items (1-2)</b>	<b>2,031.97</b>	<b>1,097.88</b>	<b>2,111.02</b>	<b>3,129.85</b>	<b>2,961.63</b>	<b>6,003.04</b>
4. Other income	669.80	541.31	515.59	1,201.11	1,009.70	2,328.82
<b>5. Profit from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>2,691.77</b>	<b>1,639.19</b>	<b>2,626.61</b>	<b>4,330.96</b>	<b>3,971.33</b>	<b>8,332.86</b>
6. Finance Costs	-	-	-	-	-	-
<b>7. Profit from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>2,691.77</b>	<b>1,639.19</b>	<b>2,626.61</b>	<b>4,330.96</b>	<b>3,971.33</b>	<b>8,332.86</b>
8. Exceptional items	-	-	-	-	-	-
<b>9. Profit from ordinary activities before tax (7+8)</b>	<b>2,691.77</b>	<b>1,639.19</b>	<b>2,626.61</b>	<b>4,330.96</b>	<b>3,971.33</b>	<b>8,332.86</b>
10. Tax expense	901.49	414.61	940.63	1,316.10	1,323.41	2,976.59
<b>11. Net Profit from ordinary activities after tax (9-10)</b>	<b>1,790.28</b>	<b>1,224.58</b>	<b>1,685.98</b>	<b>3,014.86</b>	<b>2,647.92</b>	<b>5,356.27</b>
12. Extraordinary items (net of tax expense)	-	-	-	-	-	-
<b>13. Net Profit for the period (11+12)</b>	<b>1,790.28</b>	<b>1,224.58</b>	<b>1,685.98</b>	<b>3,014.86</b>	<b>2,647.92</b>	<b>5,356.27</b>
14. Paid-up equity share capital (Face Value Rs 10/-)	1,659.94	1,659.94	1,659.94	1,659.94	1,659.94	1,659.94
15. Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	57,494.00
<b>16.i Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):</b>						
(a) Basic	10.79	7.38	10.16	18.16	15.95	32.27
(b) Diluted	10.79	7.38	10.16	18.16	15.95	32.27
<b>16.ii Earnings per share (after extraordinary items) (of Rs 10/- each) (not annualised):</b>						
(a) Basic	10.79	7.38	10.16	18.16	15.95	32.27
(b) Diluted	10.79	7.38	10.16	18.16	15.95	32.27

Notes :-  
 1. The above results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 29th July 2016. The above results were subjected to a "Limited Review" by the Statutory Auditors.  
 2. Figures for the previous quarter/period have been re-arranged/re-arranged wherever necessary.

Place : Mumbai  
 Date : 29th July 2016  
 Please visit us at our website [www.merck.co.in](http://www.merck.co.in)

Segment Wise Revenue, Result and Capital Employed						
Particulars	3 months ended 30/06/2016	Preceding 3 months ended 31/03/2016	Corresponding 3 months ended 30/06/2015	Year to date figures for the current period ended 30/06/2016	Year to date figures for the previous period ended 30/06/2015	Previous year ended 31/12/2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Segment Revenue</b>						
a) Pharmaceuticals	19,936.64	16,998.38	17,655.29	36,929.02	31,429.00	66,590.82
b) Chemicals	6,836.96	4,827.45	7,296.02	10,664.40	13,538.37	28,043.20
<b>Total</b>	<b>26,773.60</b>	<b>21,815.83</b>	<b>24,951.31</b>	<b>47,593.42</b>	<b>44,967.45</b>	<b>94,634.02</b>
Less: Inter segment revenue	-	-	224.15	-	364.31	683.98
<b>Net Sales and Other Operating Income</b>	<b>26,773.60</b>	<b>21,815.83</b>	<b>24,727.16</b>	<b>47,593.42</b>	<b>44,603.14</b>	<b>93,950.04</b>
<b>2. Segment Results (Profit before Tax and Interest from each segment)</b>						
a) Pharmaceuticals	2,284.76	869.85	1,488.73	3,164.61	1,963.76	5,055.48
b) Chemicals	477.89	180.82	718.72	658.51	1,045.16	2,141.97
<b>Total</b>	<b>2,762.65</b>	<b>1,050.67</b>	<b>2,207.45</b>	<b>3,823.12</b>	<b>3,008.94</b>	<b>7,197.45</b>
Less: Other un-allocable expenditure net off un-allocable income	70.88	(588.72)	(419.16)	(517.84)	(967.39)	(1,135.41)
<b>Total Profit before Tax</b>	<b>2,691.77</b>	<b>1,639.19</b>	<b>2,626.61</b>	<b>4,330.96</b>	<b>3,971.33</b>	<b>8,332.86</b>
<b>3. Capital Employed</b>						
a) Pharmaceuticals	15,435.67	15,665.17	15,634.07	15,435.67	15,634.07	15,016.00
b) Chemicals	12,836.98	15,680.41	18,791.09	12,836.98	18,791.09	17,585.10
c) Unallocated	33,896.25	29,033.95	23,520.38	33,896.25	23,520.38	26,550.84
<b>Total</b>	<b>62,168.90</b>	<b>60,379.53</b>	<b>57,945.52</b>	<b>62,168.90</b>	<b>57,945.52</b>	<b>59,153.94</b>

Particulars	As at 30.06.2016 (Unaudited)	As at 31.12.2015 (Audited)
	<b>EQUITY AND LIABILITIES</b>	
<b>Shareholders' Funds</b>		
(a) Share capital	1,659.94	1,659.94
(b) Reserves and surplus	60,508.96	57,494.00
<b>Sub-total-Shareholders' funds</b>	<b>62,168.90</b>	<b>59,153.94</b>
<b>Non-current liabilities</b>		
(a) Other non-current liabilities	386.22	444.00
(b) Long-term provisions	2,248.70	2,212.00
<b>Sub-total-Non-current liabilities</b>	<b>2,634.92</b>	<b>2,656.00</b>
<b>Current liabilities</b>		
(a) Trade payables	7,228.84	6,555.00
(b) Other current liabilities	6,641.23	6,158.82
(c) Short-term provisions	2,805.60	3,873.00
<b>Sub-total-Current liabilities</b>	<b>16,375.67</b>	<b>16,586.82</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>81,180.29</b>	<b>78,396.76</b>
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Fixed assets	13,166.93	13,673.04
(b) Deferred tax asset (net)	952.03	968.36
(c) Long-term loans and advances	8,253.20	6,714.63
<b>Sub-total - Non-current assets</b>	<b>22,361.16</b>	<b>21,356.05</b>
<b>Current assets</b>		
(a) Current investments	4,242.89	4,228.00
(b) Inventories	18,481.41	16,686.00
(c) Trade receivables	12,185.75	12,657.04
(d) Cash and cash equivalents	23,259.66	18,841.88
(e) Short-term loans and advances	2,207.35	3,444.73
(f) Other current assets	1,462.11	1,383.08
<b>Sub-total - Current assets</b>	<b>58,819.13</b>	<b>57,240.71</b>
<b>TOTAL - ASSETS</b>	<b>81,180.29</b>	<b>78,396.76</b>



*N. Krishnan*  
 N. Krishnan  
 Executive Director and Chief Financial Officer

# B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,  
Apollo Mills Compound  
N. M. Joshi Marg, Mahalaxmi  
Mumbai - 400 011  
India

Telephone +91 (22) 4345 5300  
Fax +91 (22) 4345 5399

## Review report

### To Board of Directors of Merck Limited


We have reviewed the accompanying statement of un-audited financial results ('the Statement') of Merck Limited ('the Company') for the quarter and six months ended 30 June 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 25 July 2016. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**  
Chartered Accountants

Firm's Registration No: 101248W/W-100022



**Vikas R Kasat**  
Partner

Membership No.: 105317

Mumbai  
25 July 2016

B S R & Co (a partnership firm with  
Registration No. BA61223) converted into  
B S R & Co. LLP (a Limited Liability, Partnership  
with LLP Registration No. AAB-8181)  
with effect from October 14, 2013

Registered Office:  
5th Floor, Lodha Excelus  
Apollo Mills Compound  
N. M. Joshi Marg, Mahalaxmi  
Mumbai - 400 011, India